ARTICLES BY MATTHEW PILLAR

• Where's The Case For Generative AI In Biopharmaceutical Manufacturing?

  6/12/2024

  The early use cases for AI in the biopharmaceutical industry—at least, the early public use cases—have largely come from R&D, and more specifically, target identification and molecular design. Where are the use cases in biologics manufacturing, supply chain management, QMS, and operations, and what’s holding us back?

• Bioprocessing Technology: You Are The Standard

  5/21/2024

  Single-use bioprocessing equipment engineer and expert Paul Priebe has some advice for you. Next time you catch yourself questioning an equipment standard (or the lack thereof), take a good look in the mirror. 

• Single Use In Biopharma: Beyond Savings & Sustainability

  4/17/2024

  SUT continues to trend in biopharmaceutical applications, driven largely by environmental and economic considerations. But there’s a lot more to the SUT story, including supply chain and standardization advantages. We dove headlong into those issues and more with independent SUT expert Paul Priebe and Krystal Biotech VP of Technical Operations Mark Petrich.

• Doubling Down On Biopharma's Growing Skills Drought

  3/13/2024

  The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.

• Legal And IP Protection For New Biotechs

  10/31/2023

  Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

• Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.

  11/28/2021

  Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.

• The Real Threat To Biopharma Supply Chains: Bioprocessing Materials

  5/12/2020

  The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive. 

• Does Gender Disparity In Biotech Really Matter?

  8/29/2019

  Why it does, and how one startup is winning the biotech talent wars with a diversity-centric strategy.